Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
INO-5401 by Inovio Pharmaceuticals for Glioblastoma Multiforme (GBM): Likelihood of Approval
INO-5401 is under clinical development by Inovio Pharmaceuticals and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Inovio Pharmaceuticals's INO-5401?
INO-5401 is a dna vaccine commercialized by Inovio Pharmaceuticals, with a leading Phase II program in Glioblastoma Multiforme (GBM). According...